Montag & Associates’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.9K | Hold |
72
| – | – | ﹤0.01% | 682 |
|
|
2025
Q4 | $25.1K | Hold |
72
| – | – | ﹤0.01% | 676 |
|
|
2025
Q3 | $23.1K | Sell |
72
-161
| -69% | -$50.1K | ﹤0.01% | 682 |
|
|
2025
Q2 | $90.7K | Buy |
233
+11
| +5% | +$4.42K | ﹤0.01% | 491 |
|
|
2025
Q1 | $96.3K | Hold |
222
| – | – | ﹤0.01% | 503 |
|
|
2024
Q4 | $81.7K | Sell |
222
-500
| -69% | -$209K | ﹤0.01% | 533 |
|
|
2024
Q3 | $375K | Sell |
722
-23
| -3% | -$12.3K | 0.02% | 359 |
|
|
2024
Q2 | $403K | Hold |
745
| – | – | 0.02% | 334 |
|
|
2024
Q1 | $386K | Sell |
745
-20
| -3% | -$9.95K | 0.02% | 348 |
|
|
2023
Q4 | $361K | Buy |
765
+150
| +24% | +$69.4K | 0.02% | 335 |
|
|
2023
Q3 | $268K | Hold |
615
| – | – | 0.02% | 350 |
|
|
2023
Q2 | $273K | Hold |
615
| – | – | 0.02% | 354 |
|
|
2023
Q1 | $283K | Hold |
615
| – | – | 0.02% | 341 |
|
|
2022
Q4 | $315K | Sell |
615
-43
| -7% | -$21.8K | 0.02% | 313 |
|
|
2022
Q3 | $299K | Hold |
658
| – | – | 0.02% | 315 |
|
|
2022
Q2 | $317K | Hold |
658
| – | – | 0.02% | 312 |
|
|
2022
Q1 | $323K | Buy |
658
+1
| +0.2% | +$457 | 0.02% | 338 |
|
|
2021
Q4 | $305K | Buy |
657
+200
| +44% | +$84.1K | 0.02% | 346 |
|
|
2021
Q3 | $170K | Hold |
457
| – | – | 0.01% | 405 |
|
|
2021
Q2 | $174K | Sell |
457
-29
| -6% | -$11.1K | 0.01% | 409 |
|
|
2021
Q1 | $174K | Sell |
486
-1,042
| -68% | -$335K | 0.01% | 404 |
|
|
2020
Q4 | $491K | Hold |
1,528
| – | – | 0.03% | 275 |
|
|
2020
Q3 | $410K | Sell |
1,528
-3,651
| -70% | -$982K | 0.03% | 242 |
|
|
2020
Q2 | $1.36M | Sell |
5,179
-113
| -2% | -$30.1K | 0.12% | 150 |
|
|
2020
Q1 | $1.2M | Buy |
5,292
+867
| +20% | +$236K | 0.12% | 154 |
|
|
2019
Q4 | $1.34M | Buy |
4,425
+3,055
| +223% | +$841K | 0.11% | 165 |
|
|
2019
Q3 | $329K | Sell |
1,370
-1,534
| -53% | -$420K | 0.03% | 251 |
|
|
2019
Q2 | $820K | Sell |
2,904
-20,020
| -87% | -$5.47M | 0.07% | 187 |
|
|
2019
Q1 | $6.58M | Buy |
22,924
+331
| +1% | +$95.7K | 0.61% | 43 |
|
|
2018
Q4 | $5.93M | Buy |
22,593
+2,593
| +13% | +$713K | 0.64% | 41 |
|
|
2018
Q3 | $5.48M | Buy |
20,000
+3,799
| +23% | +$986K | 0.48% | 52 |
|
|
2018
Q2 | $3.86M | Sell |
16,201
-4,723
| -23% | -$1.09M | 0.4% | 69 |
|
|
2018
Q1 | $4.6M | Buy |
20,924
+13,851
| +196% | +$3.25M | 0.47% | 56 |
|
|
2017
Q4 | $1.59M | Sell |
7,073
-12,208
| -63% | -$2.6M | 0.15% | 148 |
|
|
2017
Q3 | $3.66M | Buy |
19,281
+595
| +3% | +$113K | 0.39% | 74 |
|
|
2017
Q2 | $3.52M | Buy |
+18,686
| New | +$3.36M | 0.39% | 69 |
|
Other funds holding ELV
VCM
VPM
Montag & Associates's ELV Position: Q1 2026 in Review
Montag & Associates held its Elevance Health (ELV) position steady in Q1 2026 at 72 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #682.
Montag & Associates first reported a position in ELV in Q2 2017 and has held it in 36 quarters since. The position peaked at $6.58M in Q1 2019. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Montag & Associates held 72 shares of Elevance Health worth $20.9K as of Q1 2026.
- Montag & Associates left its Elevance Health share count unchanged in Q1 2026.
- Elevance Health made up ﹤0.01% of Montag & Associates's portfolio in Q1 2026, its #682 holding.
- Montag & Associates first reported a position in Elevance Health in Q2 2017 and has held it in 36 quarters since.
- Montag & Associates's Elevance Health position peaked at $6.58M in Q1 2019.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.